BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16732321)

  • 1. Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations.
    Kjaer S; Kurokawa K; Perrinjaquet M; Abrescia C; Ibáñez CF
    Oncogene; 2006 Nov; 25(53):7086-95. PubMed ID: 16732321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation.
    Bongarzone I; Vigano E; Alberti L; Borrello MG; Pasini B; Greco A; Mondellini P; Smith DP; Ponder BA; Romeo G; Pierotti MA
    Oncogene; 1998 May; 16(18):2295-301. PubMed ID: 9620546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
    Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
    Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.
    Chappuis-Flament S; Pasini A; De Vita G; Ségouffin-Cariou C; Fusco A; Attié T; Lenoir GM; Santoro M; Billaud M
    Oncogene; 1998 Dec; 17(22):2851-61. PubMed ID: 9879991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
    Kawai K; Iwashita T; Murakami H; Hiraiwa N; Yoshiki A; Kusakabe M; Ono K; Iida K; Nakayama A; Takahashi M
    Cancer Res; 2000 Sep; 60(18):5254-60. PubMed ID: 11016655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
    Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
    Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unexpected structures formed by the kinase RET C634R mutant extracellular domain suggest potential oncogenic mechanisms in MEN2A.
    Liu Y; De Castro Ribeiro O; Haapanen O; Craven GB; Sharma V; Muench SP; Goldman A
    J Biol Chem; 2022 Oct; 298(10):102380. PubMed ID: 35985422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.
    Iervolino A; Iuliano R; Trapasso F; Viglietto G; Melillo RM; Carlomagno F; Santoro M; Fusco A
    Cancer Res; 2006 Jun; 66(12):6280-7. PubMed ID: 16778204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
    Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.
    Carlomagno F; Salvatore G; Cirafici AM; De Vita G; Melillo RM; de Franciscis V; Billaud M; Fusco A; Santoro M
    Cancer Res; 1997 Feb; 57(3):391-5. PubMed ID: 9012462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
    Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
    Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.
    Gorla L; Mondellini P; Cuccuru G; Miccichè F; Cassinelli G; Cremona M; Pierotti MA; Lanzi C; Bongarzone I
    Mol Carcinog; 2009 Mar; 48(3):220-231. PubMed ID: 18756447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of leukocyte common antigen-related protein on biochemical and biological activities of RET-MEN2A and RET-MEN2B mutant proteins.
    Qiao S; Iwashita T; Furukawa T; Yamamoto M; Sobue G; Takahashi M
    J Biol Chem; 2001 Mar; 276(12):9460-7. PubMed ID: 11121408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of gene expression induced by RET with MEN2A or MEN2B mutation.
    Watanabe T; Ichihara M; Hashimoto M; Shimono K; Shimoyama Y; Nagasaka T; Murakumo Y; Murakami H; Sugiura H; Iwata H; Ishiguro N; Takahashi M
    Am J Pathol; 2002 Jul; 161(1):249-56. PubMed ID: 12107109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanism of activation and superactivation of Ret tyrosine kinases by ultraviolet light irradiation.
    Kato M; Iwashita T; Akhand AA; Liu W; Takeda K; Takeuchi K; Yoshihara M; Hossain K; Wu J; Du J; Oh C; Kawamoto Y; Suzuki H; Takahashi M; Nakashima I
    Antioxid Redox Signal; 2000; 2(4):841-9. PubMed ID: 11213488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET activation by germline MEN2A and MEN2B mutations.
    Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
    Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.
    Michiels FM; Chappuis S; Caillou B; Pasini A; Talbot M; Monier R; Lenoir GM; Feunteun J; Billaud M
    Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3330-5. PubMed ID: 9096393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic Ret tyrosine kinases.
    Kato M; Iwashita T; Takeda K; Akhand AA; Liu W; Yoshihara M; Asai N; Suzuki H; Takahashi M; Nakashima I
    Mol Biol Cell; 2000 Jan; 11(1):93-101. PubMed ID: 10637293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.